Biotech and National Security: Considerations for Receiving Foreign Investment and CFIUS

4:15 PM - 5:15 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 252AB
Representatives from the Committee on Foreign Investment in the United States (CFIUS) will speak to national security risks unique to the biotech industry. For example, genetic, biometric, and health information are especially sensitive categories of personal data, but often necessary for biotech companies to conduct testing and trials. How can the industry protect this data from threat actors who would use it to harm national security?

As companies develop cutting-edge treatments and technology to help people live better, those same tools can be used to cause irreparable harm. How can we work together to prevent them from getting into the wrong hands? To protect national security, knowing your investor is crucial. CFIUS will take a deep dive into foreign investors, including limited partners, so due diligence by parties at the outset can facilitate the CFIUS process.
Vice President, Emerging Companies and Capital Formation
Deputy Director, Foreign Investment Review, Office of Global Investment and Economic Security
U.S. Department of Defense
CFIUS Staff Chair and Director, Office of Investment Review & Investigation
U.S. Department of the Treasury